Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
NCT06135194
·
clinicaltrials.gov ↗
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
T-DXd
Sponsor
Beijing 302 Hospital